<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879085</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI# 12-104</org_study_id>
    <nct_id>NCT01879085</nct_id>
  </id_info>
  <brief_title>Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma</brief_title>
  <acronym>GemTax</acronym>
  <official_title>Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melissa Burgess, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study
      designed to determine the safety, tolerability, and recommended dose of the combination.

      During the Phase 2 portion of the study, we will assess progression-free survival (PFS),
      overall survival (OS),overall response rate (ORR), correlative endpoints, DNA methylation
      measured by microarray, and expression level of the genes as measured by microarray
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1b

        -  To determine the dose of vorinostat that can be safely combined with gemcitabine and
           docetaxel in patients with advanced sarcomas.

        -  To characterize the Pharmacokinetics (PK) and Pharmacodynamics (PD) of vorinostat when
           combined with gemcitabine and docetaxel in patients with advanced sarcomas.

      Phase 2

        -  To determine the safety and efficacy of gemcitabine and docetaxel in combination with
           vorinostat in patients with advanced sarcomas. The hypothesis is that gemcitabine and
           docetaxel + vorinostat will be safe and will improve the 6-months progression-free rates
           (PFR) of the combination by 20% (from 20% to 40%).

        -  To determine the objective response rate, progression-free, and overall survival of
           patients with advanced sarcomas treated with gemcitabine and docetaxel + vorinostat;

        -  To develop a predictive molecular signature of response to treatment in advanced
           sarcomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For phase 1 portion: To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination.</measure>
    <time_frame>5 years or until disease progression/survival</time_frame>
    <description>To determine the dose of vorinostat that can be safely combined with gemcitabine and docetaxel in patients with advanced sarcomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For phase 2 portion: Six-month progression-free survival rate (PFR).</measure>
    <time_frame>six months progression-free survival</time_frame>
    <description>To determine the safety and efficacy of gemcitabine and docetaxel in combination with vorinostat in patients with advanced sarcomas using the Phase 2 recommended dose (RP2D).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years or until disease progression/survival</time_frame>
    <description>To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years or until disease progression/survival</time_frame>
    <description>To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) as determined by RECIST criteria.</measure>
    <time_frame>5 years or until disease progression/survival</time_frame>
    <description>To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 IV over 60 minutes on day 8 every 21 days (1 cycle).</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, Gem will be given over 67.5 minutes at 10 mg/m2/min.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>will be given orally at the specified dose levels (Table 2) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle).</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Administered on day 9 subcutaneously at 6 mg.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed soft tissue sarcoma with evidence of
             metastatic or unresectable disease.

          -  Patients must have measurable disease by RECIST 1.1.

          -  Up to 32 prior cytotoxic chemotherapy regimens in the metastatic setting are allowed.
             Adjuvant chemotherapy or targeted therapy will not be considered a prior line of
             treatment.

          -  Age ≥18 years.

          -  ECOG performance status ≤2 (Karnofsky ≥60%).

          -  Life expectancy of greater than 12 weeks.

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥3,000/µL

               -  absolute neutrophil count ≥1,500/µL

               -  platelets ≥100,000/µL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) ≤1.5 X institutional upper limit of normal (ULN)

               -  creatinine ≤1.5 X institutional upper limit of normal (ULN)

          -  Peripheral neuropathy, if present, should be ≤grade 1.

          -  Women of Child bearing potential MUST use contraceptives.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  The following specific histologic subtypes of soft tissue sarcomas will be excluded:
             GIST, Kaposi's sarcoma, mesothelioma, dermatofibrosarcoma, chordoma, alveolar
             soft-part sarcoma. Also, all bone sarcomas are excluded including Ewing's sarcoma,
             osteosarcoma, GIST, low grade chondrosarcoma, and chordoma.

          -  Patients who have had treatment with chemotherapy or radiotherapy within 4 weeks (6
             weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier.

          -  Patients who are receiving any other investigational agents.

          -  Patients with known brain metastases.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to gemcitabine, docetaxel, vorinostat, or G-CSF.

          -  Patients who have received and progressed on the combination of gemcitabine and
             docetaxel in the metastatic setting.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant and breastfeeding women

          -  Patients taking concomitant HDAC inhibitors.

          -  HIV-positive patients on combination antiretroviral treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Burgess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sant Chawla, MD</last_name>
      <phone>310-552-9999</phone>
      <email>santchawla@sarcomaoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Chua</last_name>
      <phone>(310) 552-9999</phone>
      <email>vchua@sarcomaoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sant Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burgess, MD</last_name>
      <phone>412-623-7277</phone>
      <email>burgessma@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Burgess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Melissa Burgess, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>unresectable</keyword>
  <keyword>soft</keyword>
  <keyword>tissue</keyword>
  <keyword>sarcomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

